MoonLake Immunotherapeutics (MLTX) - Total Liabilities
Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) has total liabilities worth $119.95 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MoonLake Immunotherapeutics cash flow conversion to assess how effectively this company generates cash.
MoonLake Immunotherapeutics - Total Liabilities Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of MoonLake Immunotherapeutics to evaluate the company's liquid asset resilience ratio.
MoonLake Immunotherapeutics Competitors by Total Liabilities
The table below lists competitors of MoonLake Immunotherapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shaanxi Heimao Coking Co Ltd
SHG:601015
|
China | CN¥11.98 Billion |
|
IDT Corporation
NYSE:IDT
|
USA | $307.25 Million |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥788.84 Million |
|
Superior Plus Corp
TO:SPB
|
Canada | CA$2.78 Billion |
|
UOA Development Bhd
KLSE:5200
|
Malaysia | RM522.66 Million |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
Brazil | R$30.65 Billion |
|
Gold.com, Inc.
NASDAQ:GOLD
|
USA | $3.10 Billion |
|
MBB INDUSTRIES
XETRA:MBB
|
Germany | €421.02 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down MoonLake Immunotherapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MoonLake Immunotherapeutics market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MoonLake Immunotherapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual total liabilities of MoonLake Immunotherapeutics from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $119.95 Million | +388.76% |
| 2024-12-31 | $24.54 Million | +88.08% |
| 2023-12-31 | $13.05 Million | +61.57% |
| 2022-12-31 | $8.08 Million | -62.13% |
| 2021-12-31 | $21.33 Million | +413.89% |
| 2020-12-31 | $4.15 Million | -- |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more